Robert Sinnott - USANA Health Chief Scientific Officer
| USNA Stock | USD 43.70 1.05 2.35% |
Executive
Dr. Robert A. Sinnott, M.N.S., Ph.D. is Chief Scientific Officer of the Company. From 2005 to 2016, he was Chief Science Officer of Mannatech, Inc. From 2009 to 2012, he also served as CoChief Executive Officer and from 2012 to 2016 as CEO of Mannatech. During his tenure at Mannatech, Dr. Sinnott has served to further the company proprietary science, research and development, and initiated independent clinical trials, was responsible for oversight of quality assurancequality control, global regulatory affairs, legal department, human resources, and global supply chain. Dr. Sinnott has held scientific and business positions in both industry and government over the past 25 years with experience in life sciences, chemistry, biotechnology and nutrition. For the past 18 years, he has worked directly in the dietary supplement industry both in the United States and internationally. From 2006 to 2011, Dr. Sinnott held a seat on the Board of Directors of the Council of Responsible Nutrition, the leading trade association representing ingredient suppliers and manufacturers of dietary supplements. From 2009 to 2011, Dr. Sinnott also served as chair of the Senior Scientific Advisory Committee for the CRN. The SSAC is comprised of the highestranking scientific officers of member companies. Its role is to assist the CRN with development and implementation of scientific strategy relating to scientific publications, scientific policies and programs by government agencies since 2016.
| Age | 59 |
| Tenure | 8 years |
| Address | 3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120 |
| Phone | 801 954 7100 |
| Web | https://www.usana.com |
Robert Sinnott Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Sinnott against USANA Health stock is an integral part of due diligence when investing in USANA Health. Robert Sinnott insider activity provides valuable insight into whether USANA Health is net buyers or sellers over its current business cycle. Note, USANA Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell USANA Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Sinnott over a month ago Disposition of 45 shares by Robert Sinnott of USANA Health at 46.555 subject to Rule 16b-3 |
USANA Health Management Efficiency
The company has return on total asset (ROA) of 0.0946 % which means that it generated a profit of $0.0946 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1369 %, meaning that it created $0.1369 on every $100 dollars invested by stockholders. USANA Health's management efficiency ratios could be used to measure how well USANA Health manages its routine affairs as well as how well it operates its assets and liabilities. At present, USANA Health's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.25, whereas Return On Capital Employed is forecasted to decline to 0.26. At present, USANA Health's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 37.4 M, whereas Non Current Assets Total are forecasted to decline to about 110.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| George Yuhas | Central Garden Pet | 65 | |
| Mary Sagona | Seneca Foods Corp | N/A | |
| William Pennington | Central Garden Pet | N/A | |
| Mary Kehoe | J J Snack | 62 | |
| Amiee Castleberry | Seneca Foods Corp | N/A | |
| Howard Machek | Central Garden Pet | 61 | |
| Bjoern Leyser | J J Snack | N/A | |
| Chris Cole | Bridgford Foods | N/A | |
| Amiee Castleberry | Seneca Foods Corp | N/A | |
| Lynwood Mallard | J J Snack | 55 | |
| Michael Bridgford | Bridgford Foods | 42 | |
| Aron Kolosik | Central Garden Pet | N/A | |
| Friederike Edelmann | Central Garden Pet | N/A | |
| Ken Elsbury | Central Garden Pet | N/A | |
| Sarah Mortensen | Seneca Foods Corp | 73 | |
| Robert Cranmer | J J Snack | 67 | |
| Mary Sagona | Seneca Foods Corp | N/A | |
| George Yuhas | Central Garden Pet | 65 | |
| Howard Machek | Central Garden Pet | 61 | |
| John Exner | Seneca Foods Corp | 62 | |
| Aron Kolosik | Central Garden Pet | N/A | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0946 |
USANA Health Sciences Leadership Team
Elected by the shareholders, the USANA Health's board of directors comprises two types of representatives: USANA Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of USANA. The board's role is to monitor USANA Health's management team and ensure that shareholders' interests are well served. USANA Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, USANA Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Wood, Independent Director | ||
| David Wentz, Co-CEO | ||
| G Iiekking, CFO | ||
| Andrew Masuda, Director Relations | ||
| Scott Nixon, Additional Independent Director | ||
| Patrique Richards, Executive Development | ||
| Donald Williams, Independent Director | ||
| Paul Jones, CFO, Principal Accounting Officer and Chief Leadership Devel. Officer | ||
| Peggie Pelosi, Independent Director | ||
| Frederic Winssinger, Independent Director | ||
| Joshua Foukas, General Officer | ||
| Jerry McClain, Independent Director | ||
| Douglas Hekking, Chief Officer | ||
| James Bramble, Chief Legal Officer and Corporate Secretary | ||
| John Cuomo, Executive Technology | ||
| Douglas Braun, Chief Marketing Officer | ||
| Walter Noot, Chief Operating Officer | ||
| Brian Dixon, Executive Education | ||
| Deborah Woo, President of Asia and Greater China | ||
| Richard Williams, Independent Director | ||
| P Foukas, Chief Legal Officer, General Counsel and Corporate Secretary | ||
| Ronald Poelman, Board Secretary, Independent Director | ||
| Donald Wiiliam, Independent Director | ||
| Josh Foukas, Executive Vice President - Legal | ||
| Feng Peng, Independent Director | ||
| Kevin Guest, Chairman of the Board, Chief Executive Officer | ||
| Xia Ding, Independent Director | ||
| Daniel Macuga, Chief Communications and Marketing Officer | ||
| Robert Anciaux, Independent Director | ||
| David Mulham, Chief Field Development Officer | ||
| Gilbert Fuller, Lead Independent Director | ||
| Myron Wentz, Founder and Chairman | ||
| John Fleming, Independent Director | ||
| Jim Brown, Chief Production Officer | ||
| Brent Neidig, Chief Officer and Managing Director of China | ||
| G Hekking, Chief Financial Officer | ||
| Robert Sinnott, Chief Scientific Officer | ||
| Robert Auciaux, Independent Director | ||
| Dr MNS, Chief Officer |
USANA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is USANA Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0946 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 543.8 M | ||||
| Shares Outstanding | 19.24 M | ||||
| Shares Owned By Insiders | 41.28 % | ||||
| Shares Owned By Institutions | 55.68 % | ||||
| Number Of Shares Shorted | 248.95 K | ||||
| Price To Earning | 8.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether USANA Health Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of USANA Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Usana Health Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Usana Health Sciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for USANA Stock analysis
When running USANA Health's price analysis, check to measure USANA Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy USANA Health is operating at the current time. Most of USANA Health's value examination focuses on studying past and present price action to predict the probability of USANA Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move USANA Health's price. Additionally, you may evaluate how the addition of USANA Health to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is USANA Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of USANA Health. If investors know USANA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about USANA Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.32 | Earnings Share 3.3 | Revenue Per Share 47.845 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0946 |
The market value of USANA Health Sciences is measured differently than its book value, which is the value of USANA that is recorded on the company's balance sheet. Investors also form their own opinion of USANA Health's value that differs from its market value or its book value, called intrinsic value, which is USANA Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because USANA Health's market value can be influenced by many factors that don't directly affect USANA Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between USANA Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if USANA Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, USANA Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.